Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
34.39
-0.12 (-0.35%)
At close: Oct 20, 2025, 4:00 PM EDT
34.39
0.00 (0.00%)
After-hours: Oct 20, 2025, 4:10 PM EDT
Galapagos NV Revenue
Galapagos NV had revenue of 65.29M EUR in the quarter ending June 30, 2025, a decrease of -16.16%. This brings the company's revenue in the last twelve months to 275.61M, up 5.43% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
275.61M EUR
Revenue Growth
+5.43%
P/S Ratio
7.03
Revenue / Employee
391,490 EUR
Employees
704
Market Cap
2.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GLPG News
- 4 days ago - Galapagos Announces Appointment of Fred Blakeslee as General Counsel - GlobeNewsWire
- 19 days ago - Biotechnology firm Galapagos receives offers for cell-therapy business - Reuters
- 19 days ago - Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business - GlobeNewsWire
- 2 months ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 2 months ago - Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma - GlobeNewsWire
- 3 months ago - Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation - GlobeNewsWire
- 3 months ago - Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors - GlobeNewsWire
- 3 months ago - Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update - GlobeNewsWire